SANUWAVE Health, Inc. announced that it has received $2.9 million in funding from Premier Shockwave, Inc.
January 10, 2018
Share
On January 10, 2018, SANUWAVE Health, Inc. (OTCPK:SNWV) closed the transaction. The company has issued notes for gross proceeds of $1,380,310 in its final tranche closing. The company also issued 12,548,273 warrants in its tranche close. The company has received $130,000 in the transaction from 42 investors pursuant to exemption provided under Regulation D.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
